Fundraise

ODAIA lands $15M Series C, ties up with Publicis agency PHM

What's the deal? ODAIA, an AI company that builds predictive commercial intelligence for pharma, has closed a $15 million Series C led by Monograph CapitalDealroom has a profile for this one. Try Dealroom → and anchored by strategic investor PHMDealroom has a profile for this one. Try Dealroom →, the US health media agency owned by Publicis GroupeDealroom has a profile for this one. Try Dealroom →. Series A backers BDC Capital, Flint CapitalDealroom has a profile for this one. Try Dealroom →, Innospark VenturesDealroom has a profile for this one. Try Dealroom →, and Graphite VenturesDealroom has a profile for this one. Try Dealroom → returned, as did Series B investors Threshold Ventures and Wittington VenturesDealroom has a profile for this one. Try Dealroom →.

What's the endgame? ODAIA's platform predicts patient journeys, flags missed prescription opportunities, and tells pharma sales and marketing teams which healthcare professionals (HCPs) to reach, through which channel, and when. Brand teams codify their strategy once, and the system turns it into HCP-level decisions that scale to new brands or therapeutic areas through configuration.

What's the money for? ODAIA will deepen its work with the enterprise pharma accounts it already serves and keep building out the platform. It lists Novo Nordisk, GSK, and Ardelyx among more than 40 brands onboarded.

Why now? "Pharma has proven that AI works in commercial. The hard part now is scaling it," said chief executive officer and co-founder Philip Poulidis. The round arrives with a commercial agreement making PHM ODAIA's exclusive US agency partner, bringing the platform to the agency's pharma clients to coordinate digital media and field-sales outreach.

The deal builds on ODAIA's $25 million Series B in 2023, co-led by Threshold Ventures and Monograph Capital. Charles Conn, co-founder and partner at Monograph, which led this round, said the company helps "large and specialty pharma brands reach the physicians whose patients need their therapies most."

The signal: The round is modest next to the much larger financings in drug-discovery AI, but the PHM tie-up marks a shift from selling standalone software toward distribution through an established marketing partner. Its payoff will hinge on whether that channel converts into broader adoption across pharma.

Read more: prnewswire.com

Image credit: ODAIA, via PR Newswire

More top stories